Penetration of amphotericin B in human lung tissue after single liposomal amphotericin B (AmBisome) infusion

被引:16
作者
Demartini, G
Lequaglie, C
Massone, PPB
Scaglione, F
Fraschini, F
机构
[1] Univ Milan, Dept Pharmacol, I-20129 Milan, Italy
[2] Ist Nazl Tumori, Div Thorac Surg, Milan, Italy
关键词
liposomal amphotericin B; lung tissue distribution; humans;
D O I
10.1179/joc.2005.17.1.82
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The distribution of amphotericin B in lung tissue was studied in 18 patients with primary or secondary lung cancer who underwent thoracotomy and pulmonary resection. At different times before surgery the patients were treated with liposomal amphotericin B 1.5 mg/kg by i.v. infusion over 1h. Blood and lung tissue samples were collected during surgery (one subject for each collecting time) and assayed for amphotericin B levels by HPLC. Due to surgical requirements, it was possible to obtain data from the loth to the 25(th) h after the end of infusion. Plasma amphotericin B concentrations progressively decreased from 3.4 mu g/ml at the loth h to 1 mu g/ml at the 25(th) h after the end of intravenous infusion. In lung tissue samples the lowest amphotericin B concentration (about 1 mu/g) was observed at the loth h, then a progressive increase was observed with the highest value (2.5 mu g/g) determined at the 25(th) h.
引用
收藏
页码:82 / 85
页数:4
相关论文
共 22 条
[1]  
Adler-Moore J.P., 1993, Journal of Liposome Research, V3, P429, DOI DOI 10.3109/08982109309150729
[2]   Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate [J].
Bekersky, I ;
Fielding, RM ;
Dressler, DE ;
Lee, JW ;
Buell, DN ;
Walsh, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :834-840
[3]   Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans [J].
Bekersky, I ;
Fielding, RM ;
Dressler, DE ;
Lee, JW ;
Buell, DN ;
Walsh, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :828-833
[4]   Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome®) in beagle dogs [J].
Bekersky, I ;
Boswell, GW ;
Hiles, R ;
Fielding, RM ;
Buell, D ;
Walsh, TJ .
PHARMACEUTICAL RESEARCH, 1999, 16 (11) :1694-1701
[5]   Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome®):: A 91-day study in rats [J].
Bekersky, I ;
Boswell, GW ;
Hiles, R ;
Fielding, RM ;
Buell, D ;
Walsh, TJ .
PHARMACEUTICAL RESEARCH, 2000, 17 (12) :1494-1502
[6]   AmBisome (Liposomal amphotericin B): A comparative review [J].
Boswell, GW ;
Buell, D ;
Bekersky, I .
JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (07) :583-592
[7]   LIPOSOMAL AMPHOTERICIN-B (AMBISOME) IN THE TREATMENT OF FUNGAL-INFECTIONS IN NEUTROPENIC PATIENTS [J].
CHOPRA, R ;
BLAIR, S ;
STRANG, J ;
CERVI, P ;
PATTERSON, KG ;
GOLDSTONE, AH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 28 :93-104
[8]   DISTRIBUTION AND ACTIVITY OF AMPHOTERICIN-B IN HUMANS [J].
CHRISTIANSEN, KJ ;
BERNARD, EM ;
GOLD, JWM ;
ARMSTRONG, D .
JOURNAL OF INFECTIOUS DISEASES, 1985, 152 (05) :1037-1043
[9]   TISSUE DISTRIBUTION AND BIOACTIVITY OF AMPHOTERICIN-B ADMINISTERED IN LIPOSOMES TO CANCER-PATIENTS [J].
COLLETTE, N ;
VANDERAUWERA, P ;
MEUNIER, F ;
LAMBERT, C ;
SCULIER, JP ;
COUNE, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 (04) :535-548
[10]   TISSUE CONCENTRATIONS AND BIOACTIVITY OF AMPHOTERICIN-B IN CANCER-PATIENTS TREATED WITH AMPHOTERICIN-B-DEOXYCHOLATE [J].
COLLETTE, N ;
VANDERAUWERA, P ;
LOPEZ, AP ;
HEYMANS, C ;
MEUNIER, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (03) :362-368